Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.30T
Market cap1.30T
Price-Earnings ratio
46.50
Price-Earnings ratio46.50
Dividend yield
0.47%
Dividend yield0.47%
Average volume
3.16M
Average volume3.16M
High today
$1,423.11
High today$1,423.11
Low today
$1,380.00
Low today$1,380.00
Open price
$1,409.87
Open price$1,409.87
Volume
1.92M
Volume1.92M
52 Week high
$1,475.25
52 Week high$1,475.25
52 Week low
$850.51
52 Week low$850.51

Stock Snapshot

With a market cap of 1.3T, Eli Lilly(LLY) trades at $1,383.90. The stock has a price-to-earnings ratio of 46.50 and currently yields dividends of 0.47%.

During the trading session on 2026-11-18, Eli Lilly(LLY) shares reached a daily high of $1,423.11 and a low of $1,380.00. At a current price of $1,383.90, the stock is +0.3% higher than the low and still -2.8% under the high.

Trading volume for Eli Lilly(LLY) stock has reached 1.92M, versus its average volume of 3.16M.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,475.25 and a low of $850.51.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,475.25 and a low of $850.51.

LLY News

Seeking Alpha 51m
Eli Lilly gains CV reduction risk indication for Mounjaro in Canada

Eli Lilly gains CV reduction risk indication for Mounjaro in Canada Nov 18, 2026, 3:04 PM ET Eli Lilly and Company (LLY) Stock By : Jonathan Block, SA News Edit...

Eli Lilly gains CV reduction risk indication for Mounjaro in Canada
TipRanks 4h
Eli Lilly Advances Early Obesity Drug Study as Investors Watch Pipeline Progress

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Study Overview: Eli Lilly is evaluating LY4247147 in a Phase 1 study titled A...

TipRanks 4h
Eli Lilly Updates Early-Stage Study of New Obesity Drug LY4167586

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Study Overview: Eli Lilly’s official study, “A Phase 1, Randomized, Participan...

Analyst ratings

81%

of 32 ratings
Buy
81.3%
Hold
12.5%
Sell
6.3%

More LLY News

The Motley Fool 24h
Eli Lilly vs. Novo Nordisk: Which GLP-1 Stock Is a Better Buy for 2027?

The global demand for next-generation metabolic treatments has sparked a fierce competition, forcing retail investors to decide between Eli Lilly & Co. (LLY -1....

Eli Lilly vs. Novo Nordisk: Which GLP-1 Stock Is a Better Buy for 2027?
Simply Wall St 1d
Eli Lilly Showcased Its Obesity Pipeline, Is It Still 3% Undervalued?

Eli Lilly (LLY) just used ObesityWeek 2026 as a showcase for its cardiometabolic pipeline, unveiling detailed data on EloraTZP, retatrutide and oral GLP-1 pill...

Eli Lilly Showcased Its Obesity Pipeline, Is It Still 3% Undervalued?
Seeking Alpha 1d
Rythm Pharmaceuticals gains on report Eli Lilly made $150/share offer with CVR

Rhythm Pharmaceuticals (RYTM) rose 5.4% amid a report that Eli Lilly (LLY) is evaluating two possible takeover targets in the obesity market, including Rhythm a...

Rythm Pharmaceuticals gains on report Eli Lilly made $150/share offer with CVR
Benzinga 1d
Eli Lilly Inks Multibillion-Dollar Pact to Develop Precision Cancer Therapies

Eli Lilly and Co. (NYSE:LLY) entered a strategic research collaboration and licensing agreement with privately held biotechnology company Stipple Bio Inc. on Mo...

Eli Lilly Inks Multibillion-Dollar Pact to Develop Precision Cancer Therapies
TipRanks 1d
Eli Lilly Enters Cancer Licensing Deal Worth $5.9 Billion

Eli Lilly (LLY) has signed an exclusive global licensing agreement with Cambridge, Massachusetts-based biotech firm Stipple Bio to discover and commercialize ca...

TipRanks 1d
Eli Lilly’s Growth Outlook Strengthened by Pipeline, Oncology Expansion and Calytrix Acquisition; $1,650 Price Target Maintained

BMO Capital analyst Evan Seigerman maintained a Buy rating on Eli Lilly & Co yesterday and set a price target of $1,650.00. Evan Seigerman’s rating is based on...

Simply Wall St 2d
Eli Lilly Agrees $1.5 Billion Rare Blood Cancer Acquisition

Eli Lilly (NYSE:LLY) agreed to acquire privately held Calytrix Bio in a deal valued at up to US$1.5b. The transaction brings Calytrix Bio's rare blood cancer p...

Eli Lilly Agrees $1.5 Billion Rare Blood Cancer Acquisition

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.